Table 9.

Ongoing clinical trials of therapeutic anticoagulation in COVID-19

NCT number	Study name	Interventions	Sponsor
NCT04377997	Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19	Evaluation of therapeutic enoxaparin	Massachusetts General Hospital (USA)
NCT04394377	Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial	Evaluation of therapeutic anticoagulation with rivaroxaban 20 mg/day vs prophylactic enoxaparin 40 mg/day	Brazilian Clinical Research Institute (Brazil)
NCT04359277	A Randomized Trial of Anticoagulation Strategies in COVID-19	Evaluation of therapeutic high dose enoxaparin vs standard prophylactic dose	NYU Langone Health (USA)
NCT04359277	Evaluation of therapeutic high dose Enoxaparin versus standard prophylactic dose Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)	Evaluation of varying anticoagulation regimens including enoxaparin, UFH, fondaparinux, and argatroban	Weill Medical College of Cornell University (USA)
NCT04362085	Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care	Evaluation of therapeutic anticoagulation vs standard of care prophylaxis	St Michael’s Hospital (Canada)

Abbreviations: COVID-19 coronavirus disease 2019, UFH unfractionated heparin